Karen Eastham has been appointed to the board of directors of Illumina, the company announced last week. She is executive vice president, COO, and a member of the board of trustees of the Burnham Institute. Prior to that, she was senior vice president and CFO of Diversa. Eastham holds an MBA and a BS from Indiana University. She also serves on the boards of directors of Tercica, Oncosis/Cyntellect, and Salmedix, as well on the board of UCSD Athena.
Ronald Matricaria has joined the board of directors of Invitrogen, replacing William Mercer, who is retiring. Matricaria is the former chairman and CEO of St. Jude Medical. Before his term at St. Jude, he spent 23 years at Eli Lilly, where his last position was executive vice president of the pharmaceutical division and president of its North American operations. He also had held the position of CEO at Lilly subsidiary Cardiac Pacemakers. Matricaria also serves on the boards of directors of Cyberonics, VistaCare, and CardioDynamics, and is chairman of the board of Haemonetics.
Matthew Kalnik has been named senior vice president of business development of Genaissance Pharmaceuticals, where he will be responsible for the commercial-ization of the firm’s pharmacogenomic, diagnostic, and therapeutic products. Kalnik most recently held the position of executive director, head of pharmacogenomics, commercial development operations in the global prescription business at Pharmacia and then Pfizer, following its acquisition of Pharmacia. The firm also announced that Krishnan Nandabalan has been promoted to the position of vice president of corporate development, primarily responsible for expanding the firm’s HAP Technology into new markets and disease areas.